» Articles » PMID: 36947237

Sumac-rose Water Mouthwash Versus Benzydamine to Prevent Radiation-induced Oral Mucositis in Head and Neck Cancers: a Phase II Randomized Trial

Overview
Specialty Oncology
Date 2023 Mar 22
PMID 36947237
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiation-induced oral mucositis (OM) largely impairs the quality of life (QoL) of patients with head and neck cancer (HNC). Few choices with limited efficacy are available to prevent this adverse effect. This randomized trial was conducted to compare the efficacy of benzydamine (standard) and a new combination (sumac and rose water) in preventing radiation-induced OM.

Methods: This was a phase II, triple-blind, active-controlled, randomized trial. The primary endpoint was OM, and the secondary endpoints were oral pain and QoL. Besides, the possible variables defining the outcomes were analyzed using the chi-squared test (univariate analysis) and binomial regression model (multivariate analysis).

Results: Sumac-rose group had fewer high-grade OM (33% vs. 63%, odds ratio [OR] 0.28, 95% confidence interval [CI 95%] 0.08-0.93, P = 0.03) and better QoL (P < 0.05). Multivariate analysis confirmed these findings. Sumac-rose rinsing could also postpone the start of oral pain (hazard ratio [HR] 0.02, CI 95% 0.001-0.32, P = 0.001) and high-grade OM (HR 0.28, P = 0.03) compared with benzydamine.

Conclusions: The sumac-rose group had a lower OM rate and grade and higher QoL than the benzydamine group. In addition, the experimental group developed high-grade OM and oral pain later during the radiotherapy course. Further studies need to be conducted to assess the role of sumac and rose water in reducing grade 3-4 mucositis in patients who undergo chemoradiation for head and neck cancer.

Citing Articles

Comparative evaluation of the efficacy of herbal and benzydamine mouthwashes in preventing radiation-induced oral mucositis among head and neck cancer patients: a systematic review and network meta-analysis.

Mohandas R, Mohapatra S Evid Based Dent. 2025; .

PMID: 39948159 DOI: 10.1038/s41432-025-01117-8.


Mitochondrial Metabolism: A New Dimension of Personalized Oncology.

Behnam B, Taghizadeh-Hesary F Cancers (Basel). 2023; 15(16).

PMID: 37627086 PMC: 10452105. DOI: 10.3390/cancers15164058.


Sumac-rose water mouthwash versus benzydamine to prevent radiation-induced oral mucositis in head and neck cancers: a phase II randomized trial.

Ameri A, Heydarirad G, Choopani R, Poshtmahi S, Ameri P, Talebi F J Cancer Res Clin Oncol. 2023; 149(10):7427-7439.

PMID: 36947237 DOI: 10.1007/s00432-023-04687-1.


Virtual screening reveals aprepitant to be a potent inhibitor of neutral sphingomyelinase 2: implications in blockade of exosome release in cancer therapy.

Moloudizargari M, Hekmatirad S, Gharaghani S, Moghadamnia A, Najafzadehvarzi H, Asghari M J Cancer Res Clin Oncol. 2023; 149(10):7207-7216.

PMID: 36884117 DOI: 10.1007/s00432-023-04674-6.

References
1.
Ameri A, Poshtmahi S, Heydarirad G, Cramer H, Choopani R, Hajimehdipoor H . Effect of Honey-Lemon Spray Versus Benzydamine Hydrochloride Spray on Radiation-Induced Acute Oral Mucositis in Head and Neck Cancer Patients: A Pilot, Randomized, Double-Blind, Active-Controlled Clinical Trial. J Altern Complement Med. 2021; 27(3):255-262. DOI: 10.1089/acm.2020.0468. View

2.
Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F . Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer. Cancer Rep (Hoboken). 2021; 5(1):e1425. PMC: 8789619. DOI: 10.1002/cnr2.1425. View

3.
Ariyawardana A, Cheng K, Kandwal A, Tilly V, Al-Azri A, Galiti D . Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019; 27(10):3985-3995. DOI: 10.1007/s00520-019-04888-w. View

4.
Bartley E, Fillingim R . Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013; 111(1):52-8. PMC: 3690315. DOI: 10.1093/bja/aet127. View

5.
Boskabady M, Shafei M, Saberi Z, Amini S . Pharmacological effects of rosa damascena. Iran J Basic Med Sci. 2013; 14(4):295-307. PMC: 3586833. View